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Abstract
Introduction p14ARF  stabilises nuclear p53, with a variable
expression of p14ARF mRNA in breast cancers. In vitro, nuclear
p14ARF  binds Hdm2 to block Hdm2-dependent
nucleocytoplasmic shuttling of p53, which is required before
cytoplasmic degradation of p53. p14ARF is negatively regulated
by p53 and through p53-independent pathways. No studies
have yet examined levels of p14ARF protein expression in breast
cancer and their relationship to Hdm2/p53 immunoreactivity or
subcellular localisation. Previously, immunohistochemical
expression of cytoplasmic p14ARF, p53 and Hdm2 has been
described. HER-2 (c-erbB2/neu) predicts prognosis and
interacts with the p14ARF/Hdm2 pathway to inactivate p14ARF
and to influence Hdm2 activity and localisation. This study
examined p14ARF and p53/Hdm2 expression and subcellular
localisation by using immunohistochemistry in a series of
invasive ductal breast cancers (IDCs) with concomitant ductal
carcinoma in situ (DCIS), to evaluate whether findings in vitro
were related to clinicopathological parameters such as HER-2
and their effect on patient outcome.
Methods The 4C6 anti-p14ARF monoclonal antibody and Dako
Envision Plus system were used to evaluate p14ARF expression
in 103 patients; p53/Hdm2 staining was performed.
Results p14ARF  was evaluable in 96 patients, with nuclear
p14ARF expression (modified Quick-score ≥ 3) in 79% (n = 76)
of IDCs and in associated DCIS in 74 patients. Cytoplasmic
p14ARF  was detectable in 23 breast cancers. Nuclear and
cytoplasmic p14ARF showed no correlation with p53 subcellular
immunoreactivity. Increasing levels of cytoplasmic p14ARF were
associated with nuclear and cytoplasmic Hdm2 expression (P <
0.001). Subcellular ARF expression was not associated with
clinicopathological parameters, and although not an
independent prognosticator, these preliminary findings suggest
that cytoplasmic p14ARF  might be associated with a better
overall survival (P = 0.09; log rank). The association between
HER-2 positivity and nuclear p14ARF (P = 0.038), as well as
nuclear Hdm2 (P = 0.019), reflects the in vitro findings of HER-
2 interaction with the ARF/Hdm2 pathway. Cytoplasmic p53
and Hdm2 expression might have biological implications,
through an association of cytoplasmic p53 with increased
tumour proliferation (P  = 0.005), and an improved overall
survival (P = 0.002, log rank) in cytoplasmic Hdm2-expressing
tumours, that independently predict favourable overall survival
(P = 0.02) and disease-free survival (P = 0.03).
Conclusions Nuclear p14ARF expression is similar in IDCs and
DCIS and is associated with Hdm2 immunoreactivity. Nuclear
p14ARF and Hdm2 might be regulated by HER-2. Clearly, our
findings in vivo suggest a complexity of p14ARF/Hdm2 and p53
pathways in which consideration of cytoplasmic p14ARF and
Hdm2 might have tumorigenic implications.
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Introduction
The development and growth of breast cancers result from
the inactivation of p53 or retinoblastoma (pRb) tumour sup-
pressor proteins that regulate cell cycle control. Such reg-
ulatory pathways trigger cell cycle arrest or apoptosis in
response to intracellular challenges such as DNA damage,
hypoxia and oncogene activation, with preservation of
genomic stability [1]. pRb maintains checkpoint integrity
through binding and blocking E2F transcription factors, a
process reinforced by the G1 cyclin-dependent kinase
inhibitor p16INK4a [2]. Similarly, p53 accumulates to tran-
scriptionally activate the cyclin-dependent kinase inhibitor
cc = Spearman correlation coefficient; DCIS = ductal carcinoma in situ; DFS = disease-free survival; ER = oestrogen receptor; GPG = good prog-
nostic group; HRP = horseradish peroxidase; IDC = invasive ductal cancer; MPG = moderate prognostic group; MQS = modified Quick-score; NPI 
= Nottingham Prognostic Index; OS = overall survival; PPG = poor prognostic group; pRb = retinoblastoma protein; TBS = Tris-buffered saline.Breast Cancer Research    Vol 6 No 5    Vestey et al.
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p21WAFI/CIPI, as well as its own negative regulator Hdm2
(human Mdm2; murine double minute 2), which terminates
the p53 response. Nuclear retention of p53 underlines its
tumour suppressor response and suggests an additional
pathway for disabling p53 over and above its mutation in
more than 50% of human cancers [3-5]. In an autoregula-
tory feedback loop, Hdm2 maintains low levels of p53 in
normal non-stressed cells and inhibits nuclear p53 through
multiple and diverse mechanisms. Hdm2 binds p53 to
inhibit its transactivation function and shuttles p53 from the
nucleus to the cytoplasm to facilitate its degradation [6-8].
Hdm2 is also an E3 ubiquitin ligase that targets p53 for the
ubiquitin-dependent 26S proteosome in the cytoplasm [9].
The INK4a/ARF gene locus on chromosome 9p21
encodes p16INK4a and p14ARF, both of which act in tumour
surveillance and link the pRb and p53 pathways [2,10-14].
p14ARF is encoded from an alternative, but partly overlap-
ping, reading frame together with p16INK4a [15], such that
ARF has a separate first exon (1β) that splices into common
exons 2 and 3, shared with p16INK4a. These proteins inde-
pendently target two cell cycle control pathways, with
p16INK4a  inhibiting cyclin D1/cyclin-dependent kinases
within the pRb pathway and p14ARF inhibiting the oncopro-
tein Hdm2 within the p53 pathway [10-14]. ARF expres-
sion and activation occur through mitogenic signals such
as Myc, E1A, E2F1, Ras and v-Abl, stabilising p53, fol-
lowed by cell cycle arrest or apoptosis [16,17]. Conse-
quently, ARF connects the pRb and p53 pathways, with
excessive proliferative signalling via pRb activating arrest
mechanisms by p53. This suggests that loss of ARF func-
tion is a major contributor to carcinogenesis in humans
[17]. p14ARF is a true tumour suppressor protein; tumours
develop spontaneously in ARF-null mice [14,18]. Promoter
hypermethylation of the INK4a and ARF genes is a major
mechanism of their inactivation, followed by hemizygous
deletions [2,10,11,19]. Breast cancers rarely demonstrate
homozygous deletions of either gene, with no mutations of
ARF [2,19-21].
ARF expression in vitro and in vivo is associated with a G1
or G2 cell cycle arrest or apoptosis after inappropriate
mitogenic stimuli or DNA damage [10-13,22,23]. Although
these effects in large part relate to activation of the p53
pathway, recent reports suggest that p14ARF  inhibits
growth independently of p53 [12,17,23,24]. Low or unde-
tectable p14ARF expression in normal tissues and its func-
tion independently of p53 in highly proliferating,
homeostatic tissues, in comparison with tumours, suggests
that p14ARF function has yet to be completely established
[17,24]. Subcellular localisation of p14ARF is preferentially
nucleolar or nuclear, where it binds Hdm2 to inhibit the lat-
ter's activities towards p53 [15,25-27]. ARF-bound Hdm2
blocks Hdm2-dependent nucleocytoplasmic shuttling of
p53, to produce nuclear retention and activation of p53
[13,27]. Further, ARF averts degradation of p53 by inhibit-
ing Hdm2-dependent ubiquitination of p53 in vivo
[13,28,29]. p14ARF acts upstream of p53 and is subject to
its negative feedback regulation, suggesting that p53
mutations or its inactivation by HDM2  amplification are
often accompanied by overexpression of ARF [10-14,30].
p53-positive tumours are also likely to have sustained epi-
static mutations such as HDM2 amplification or ARF loss
[11]. Inactivation of ARF might occur through the overex-
pression of several ARF repressors, including Twist and
Tbx-2 in breast cancers and Bmi-1 in other tumours
[31,32].
Nuclear import and export is a feature of both p53 and
Hdm2 with implications for their functional regulation, such
that cytoplasmic p53 is associated with tumours with a
poor prognosis [3-6,8]. Just as Hdm2 regulates the nuclear
export of p53, in vivo evidence suggests that ARF influ-
ences the subcellular localisation of Hdm2 [21]. Cytoplas-
mic ARF occurs through binding to Pex19p with evidence
of weak to moderate cytoplasmic staining in human
tumours, whereas two studies disregarded cytoplasmic
p14ARF expression [33-37]. In a single in vitro study, mouse
p19ARF binds a cytoplasmic protein Pex19p (cloned from
mouse testis) in normal cells (NIH 3T3) [33]. Consequently,
the subcellular localisation of these proteins and the rela-
tionship between their levels of expression are likely to be
important in evaluating breast cancers and their develop-
ment from pre-invasive ductal carcinoma in situ (DCIS) to
invasive disease.
Previous studies have examined p14ARF mRNA expression
in breast cancers, with evidence suggesting altered expres-
sion and an association with p53 [38,39]. The aim of this
study was to evaluate the levels of protein expression for
p14ARF in relation to Hdm2 and p53 using immunohisto-
chemistry in DCIS and invasive ductal breast cancers
(IDCs), including the study of their subcellular localisation.
So far, no studies have examined p14ARF/Hdm2 and p53 in
relation to clinicopathological parameters and prognosis in
breast cancer. We have shown nuclear p14ARF expression
in 79% of IDCs and in associated DCIS in 74 patients.
Cytoplasmic p14ARF was detectable in 23 breast cancers.
Levels of expression and subcellular localisation for
p14ARF, Hdm2 and p53 were similar in IDCs and DCIS.
ARF expression showed no correlation with p53 immuno-
reactivity and was associated with Hdm2 nuclear and cyto-
plasmic expression. HER-2-positive breast cancers were
associated with nuclear p14ARF and nuclear Hdm2 immu-
noreactivity. Our preliminary findings suggest that cytoplas-
mic p14ARF  and cytoplasmic Hdm2-expressing breast
cancers might be associated with a better outcome.Available online http://breast-cancer-research.com/content/6/5/R571
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Table 1
Clinicopathological variables in the patients entered into this study
Characteristic No. of patients (%)
Total 103 (100)
Age (years)
≤50 31 (30)
>50 72 (70)
Invasive tumours
Lymph node status
Negative 37 (41)
Positive 53 (59)
Not assessed 13
Invasive tumour grade
Grade I 16 (16)
Grade II 51 (49)
Grade III 36 (35)
Invasive tumour size (cm)
≤2 cm 53 (52)
>2 cm 48 (48)
Multifocal 2
Lymphovascular invasion
Present 50 (50)
Absent 50 (50)
Not assessed 3
NPI
GPG < 3.4 34 (39)
MPG 3.4–5.4 37 (42)
PPG > 5.4 17 (19)
Not possible to calculate 15
ER (quick-score)
Positive (4–8) 63 (64)
Negative (0–3) 36 (36)
Not assessed 4
HER-2 IHC
Negative (0/1+) 87 (84)
Positive (2+/3+) 16 (16)
Ki67 IHC
Low proliferation, <10% 51 (50)
High proliferation, ≥10% 52 (50)
Ductal carcinoma in situ
VNPCBreast Cancer Research    Vol 6 No 5    Vestey et al.
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Methods
Patients
The study included 103 patients aged 26–88 years
(median 59 years) with IDC of the breast, in association
with concomitant DCIS diagnosed between 1996 and
2000 at the Bristol Royal Infirmary, Bristol, UK (Table 1).
Eligibility criteria were histological diagnosis of IDC and
DCIS, no distant metastases, and unilateral tumour.
Regional Ethics Committee approval was granted before
commencement of the study. Axillary lymphadenopathy
was evaluable in 90 patients: 37 (41%) of the patients
were lymph node negative, and 53 (59%) were node posi-
tive (N1 [mobile ipsilateral] or N2 [fixed ipsilateral]). No axil-
lary surgery was undertaken in the remaining 13 patients
because of age-related co-morbidity.
Clinicopathological subgroups were analysed in accord-
ance with the Nottingham Prognostic Index (NPI) and
divided into good (GPG), moderate (MPG) and poor (PPG)
prognostic groups as described, with a modification that
included no assessment of the internal mammary lymph
nodes [40]. Evaluation of the NPI was precluded in 15
patients because of non-evaluable regional lymphadenopa-
thy and tumour size. Similarly, subgroups of DCIS were
analysed in accordance with the Van Nuys Pathologic
Classification (Table 1), which was not assessable in six
patients [41]. The design of the study to include represent-
ative samples of synchronous IDC and DCIS precluded
analysis by the Van Nuys Prognostic Index [41]. Adjuvant
treatment groups comprised tamoxifen in 60 patients (27
GPG, 16 MPG, 4 PPG and 13 no NPI), and cyclophospha-
mide–methotrexate–5-fluorouracil-containing and anthra-
cycline-containing regimes in 17 and 21 patients,
respectively (4 GPG, 19 MPG, 13 PPG and 2 no NPI). Five
patients received no adjuvant treatment. The median fol-
low-up duration was 51 months (range 6–120 months). All
were primary tumours with the exception of six local tumour
recurrences, which were excluded from the analysis of
patient outcome (see Table 4 and Fig. 3).
Tumour samples were collected shortly after surgery and
were fixed in buffered formalin for 24–48 hours at room
temperature (20–22°C). Tumours were classified in
accordance with the guidelines of the UK National Health
Service Breast Screening Programme [42] and were
graded by the modified Bloom's grading system described
by Elston and Ellis [43]. Oestrogen receptor (ER) immu-
nostaining was performed with a standard three-layered
streptavidin–avidin–biotin horseradish peroxidase (HRP)
method with a mouse anti-human ER primary antibody
(M0747, 1:100 dilution; Dako, Ely, UK) and a biotinylated
rabbit anti-mouse secondary antibody (E0354 1:350 dilu-
tion; Dako). Expression of ER was assessed with Quick-
score (0–8) and classified as positive (4–8; more than 3)
or negative (0–3; 3 or less) in five high-power fields [44].
Tumour proliferation was assessed with nuclear Ki67
immunostaining (polyclonal rabbit anti-human Ki67 antigen;
A0047, 1:100 dilution; Dako). A goat anti-rabbit biotin-
labelled polypeptide (E432, 1:400 dilution; Dako) was
Grade I 23 (24)
Grade II 36 (37)
Grade III 38 (39)
Not assessed 6
ER (quick-score)
Positive (4–8) 61 (64)
Negative (0–3) 35 (36)
Not assessed 7
HER-2 IHC
Negative (0/1+) 77 (80)
Positive (2+/3+) 19 (20)
Not assessed 7
Ki67 IHC
Low proliferation, <10% 61 (59)
High proliferation, ≥10% 42 (41)
ER, oestrogen receptor; GPG, good prognostic group; IHC, immunohistochemistry; MPG, moderate prognostic group; NPI, Nottingham 
Prognostic Index; PPG, poor prognostic group; VNPC, Van Nuys Pathologic classification.
Table 1 (Continued)
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used as a secondary antibody. Tonsillar tissue was used as
a positive control and primary antibody was replaced with
Tris-buffered saline (TBS) as a negative control. Ki67 stain-
ing was evaluated as positive or negative, with low prolifer-
ation indicative of less than 10% of positive-staining cells,
compared with high proliferation with at least 10% positiv-
ity [45]. HER-2 immunostaining was performed with the
mouse monoclonal anti-HER-2 antibody (RTU-CB11;
NovaCastra/Vector, Newcastle upon Tyne, UK) and the
Envision Plus HRP system (K4006; Dako). HER-2 expres-
sion was scored according to the degree and proportion of
membrane staining, with a score of 0 or 1+ defined as neg-
Figure 1
Examples of p14ARF, p53 and Hdm2 immunoreactivity in infiltrating ductal carcinoma of the breast Examples of p14ARF, p53 and Hdm2 immunoreactivity in infiltrating ductal carcinoma of the breast. Immunostaining was performed as described in 
the Methods section, and nuclei were counterstained with haematoxylin. (a) A tumour showing nuclear p14ARF expression in invasive ductal cancer; 
(b) a similar nuclear p14ARF positivity in concomitant ductal carcinoma in situ (DCIS). (c) Cytoplasmic p14ARF expression in invasive ductal cancer is 
representative of similar expression in DCIS. Representative examples of expression of nuclear p53 (d), cytoplasmic p53 (e), and also nuclear 
Hdm2 (f) and cytoplasmic Hdm2 (g). High-power magnification (×400) (a-g). Insets show higher-power (×1000) views of the same fields.Breast Cancer Research    Vol 6 No 5    Vestey et al.
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ative, and 2+ or 3+ as HER-2 positive [46]. Lymphovascu-
lar invasion was assessed as present or not, and was
analysed together with ER, HER-2 and Ki67 in the Depart-
ment of Pathology (by CS and CJC).
Immunohistochemistry
p14ARF immunoreactivity was evaluated with the mouse
monoclonal antibody 4C6 (kindly provided by Dr Gordon
Peters, Cancer Research UK, Lincoln's Inn Fields, London,
UK) at a 1:200 dilution of 15 µg/ml. ARF immunostaining
of IDC and DCIS was compared with formalin-fixed paraf-
fin-embedded cell buttons, using H1299 non-small cell
lung cancer cells as a positive control for p14ARF, and
MCF-7 breast cancer cells as a negative control. Further
negative controls replaced 4C6 with sero-matched IgG2a
used on previously established p14ARF-expressing breast
cancers. The 4C6 antibody with epitope recognition of car-
boxy-terminal p14ARF was chosen after testing of other
Figure 2
Relationships between subcellular localisation of p14ARF and Hdm2 Relationships between subcellular localisation of p14ARF and Hdm2. Scatter plots according to nuclear p14ARF modified Quick-score (MQS) (a, b) 
and cytoplasmic p14ARF MQS (c, d). p14ARF and Hdm2 staining was analysed as described in the Methods section. (a, b) Distribution of nuclear 
p14ARF and nuclear Hdm2 (a), and also cytoplasmic Hdm2 (b), showed no significant correlations. (c, d) Distribution of cytoplasmic p14ARF and 
nuclear Hdm2 (cC), and also cytoplasmic Hdm2 (d), showed significant correlations (P < 0.001, respectively). P values in bold (P < 0.05) indicate 
significance.
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mouse monoclonal antibodies including C-18 (Santa Cruz
Biotechnology, California) and 14PO2 (LabVision/Neomar-
kers, Fremont, California). The specificity of 4C6 has been
demonstrated previously [13,27].
Hdm2 expression was assessed with the mouse mono-
clonal antibody OP46 (Oncogene Research, CN Bio-
sciences, Nottingham, UK) that detects C-terminal Hdm2
with specificity for the 90 kDa isoform [47]. OP46 was
selected after testing with other antibodies including 2A10
and 3G5 (kindly given by AJ Levine, Rockefeller University,
New York) both of which had technical or other limitations
[48]. OP46 was used at a 1:80 dilution of 100 µg/ml and
evaluated in the context of Hdm2 overexpressing A375
malignant melanoma cells, and negatively controlled with
IgG2b, which was substituted for the primary antibody.
Biotinylated rabbit anti-mouse IgG secondary antibody
(E0354, 1:300 dilution of 1.26 mg/ml; Dako), together with
the Strept-AB Complex/HRP (0377; Dako, Glostrup, Den-
mark), was used for p14ARF and Hdm2. Technical limita-
tions precluded dual staining for ARF and Hdm2. p53
immunostaining was performed as described [49] by using
the DO7 monoclonal antibody (NovaCastra/Vector).
Breast carcinomas known to overexpress p53 with known
TP53 gene mutations and protein accumulation were used
as positive controls. Negative controls were obtained by
omitting the primary antibodies.
Formalin-fixed paraffin sections of breast cancer tissue and
cell pellets (controls) were mounted on 3-aminopropyl-tri-
ethoxysilane-coated (Sigma, Poole, Dorset, UK) glass
slides and were baked for 30 min at 56–60°C before being
dewaxed in Clearene (Surgipath Europe, Peterborough,
UK). The tissue was rehydrated by sequential immersion in
100% and 50% ethanol to distilled water. Tissue sections
were subjected to heat retrieval of antigens in citrate buffer
(pH 6) in a pressure cooker for 3 min; after cooling they
were incubated in 0.3% (v/v) hydrogen peroxide for 5 min.
Subsequently, sections were washed in tapwater and TBS
(pH 7.45). Before incubation with p14ARF and Hdm2 pri-
mary antibodies, sections were exposed to avidin and biotin
blocking solutions (Vector Laboratories, Burlingame, Cali-
fornia) for 15 min each. Further blocking was achieved
through exposure to normal rabbit serum (diluted with TBS)
for 30 min at room temperature. Primary antibody was
applied and incubated at 4°C overnight (18 hours) for
p14ARF and Hdm2, except for p53, which was incubated for
1 hour at room temperature. After washing with TBS, bioti-
nylated rabbit anti-mouse secondary antibody was applied
for 30 min at room temperature. The Strept-AB Complex/
HRP was used for the detection of p14ARF and Hdm2, and
involved an additional 30 min incubation with TBS/bioti-
nylated streptavidin/HRP. Staining was revealed by devel-
opment in the chromogen 3,3-diaminobenzidine
tetrahydrochloride  for 5–10 min before counterstaining
with haematoxylin before mounting.
Immunostaining was assessed with a Zeiss Axioskop
microscope with a 40 × Achrostig mat lens (×400 overall
magnification) and a field diameter of 0.46 mm. In the neo-
plastic cell population for IDC and DCIS, the degree of
staining intensity and the proportion of cells with p14ARF,
Hdm2 and p53 immunoreactivity in the nucleus and cyto-
plasm were individually graded semiquantitatively to pro-
duce an intensity distribution score or H-score for each
localisation, with invasive and pre-invasive components
given separate scores [50]. Initial scoring was of 10 high-
power fields; however, in view of the homogeneous stain-
ing this was reduced to 5 high-power fields. A modified
Quick-score (MQS) was used to define a score of 0–3 for
intensity (0, no staining; 1, weak staining; 2, moderate
staining; 3, strong staining) and 0–5 for distribution (0, no
staining; 1, 1% or less; 2, 1–10%; 3, 11–33%; 4, 34–
66%; 5, 67–100% of cells staining), giving an overall score
of 0–8 [44]. Sections were scored independently by two
pathologists (CS and CJC) in the Department of Pathology.
Unless otherwise stated, scores were assessed as a con-
tinuum for the purposes of statistical correlation. For the
purposes of describing p14ARF, Hdm2 and p53 immunore-
activity, tumour positivity was defined as a modified Quick-
score of 3 or more (1+/2+) (see Table 2).
Statistical analysis
Data were analysed with the SPSS 10.0 for Windows
(SPSS Incorporated, Chicago, Illinois) statistics software
and summarised with descriptive statistics. The associa-
tions between p14ARF, p53 and Hdm2 and patient charac-
teristics were assessed with the Spearman non-parametric
test for continuous variables and the χ2 test and Fisher's
exact test for categorical factors. The relationship between
p14ARF localisation and the subcellular localisation of p53
and Hdm2 was analysed with the Spearman correlation
coefficient (cc) for non-parametric data, with the p14ARF
and p53/Hdm2 MQS used as continuous variables. Analy-
ses of survival data were performed with the log-rank test
and the Cox regression model, with survival curves com-
puted with the Kaplan–Meier method. For p14ARF, p53 and
Hdm2, univariate and multivariate analyses were performed
and adjusted for the NPI score and treatment received
(tamoxifen/chemotherapy/none). Because the NPI is based
on nodal involvement, on tumour size and on grade,
patients (n = 11) with non-evaluable lymphadenopathy and
tumour size were excluded from the multivariate regression
analyses (see Table 4).Breast Cancer Research    Vol 6 No 5    Vestey et al.
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Results
p14ARF levels of expression and subcellular localisation 
in IDC and DCIS
p14ARF immunoreactivity was evaluable in the nucleus and
cytoplasm in 96 (93%) cases of IDC and in associated
DCIS in 91 (88%) cases (Fig. 1 and Table 2). ARF expres-
sion (MQS ≥ 3) was detectable in 76 (79%) IDCs and was
predominantly nuclear, with 23 breast cancers (24%) dem-
onstrating cytoplasmic p14ARF. Nuclear ARF was homoge-
neous, with no distinct pattern of nucleolar staining or
exclusive nucleolar p14ARF expression [30,34,35].
Predominant nuclear ARF might have been 'masking' the
accurate delineation of nucleolar p14ARF. Weak/moderate
nuclear ARF expression (MQS 3–5) was evident in 31
(32%) cases, with half of these showing cytoplasmic ARF
(n = 16). A loss of p14ARF nuclear immunostaining was
observed in 20 (21%) invasive breast cancers, whereas the
remaining 45 (47%) cases exhibited diffuse and strong
nuclear staining (MQS 6–8; Table 2), with a similar inten-
sity of cytoplasmic ARF in 7 cases only. A comparison
showed that the levels of p14ARF expression in DCIS were
similar to invasive disease (Table 2).
Relationships between p14ARF and p53 levels of 
expression and subcellular localisation in IDC and DCIS
p53 immunoreactivity and subcellular localisation were
evaluable in 93 (90%) cases of IDC and in DCIS in 91
(88%) cases. Immunohistochemically, p53 was detectable
in 31 (33%) IDCs (MQS ≥ 3), with similar levels of nuclear
(31 cases) and cytoplasmic (23 cases) expression (25%),
compared with p14ARF (Table 2). Weak to moderate (MQS
3–5) nuclear p53 expression was observed in 17 cases of
IDC (18%), with similar cytoplasmic staining (18 cases).
There was no nuclear or cytoplasmic p53 expression (MQS
0–2) in most IDCs (67% and 75%, respectively). Strong
nuclear p53 expression (MQS 6–8) was evident in 15% of
IDCs, with 5% of these expressing intense cytoplasmic
staining. A comparison of the levels of p53 expression and
subcellular localisation in DCIS were similar to those in IDC
(Table 2).
Sixty-six percent (n  = 46) of nuclear p14ARF-expressing
breast cancers (1+/2+) were associated with absent p53
nuclear immunoreactivity, or the possibility of wild-type p53
(Table 3). By comparison, proportionately fewer or one-
third of ARF-expressing tumours (n = 24) had nuclear p53
expression (1+/2+). These associations did not reach sta-
tistical significance. Nuclear p14ARF expression (1+/2+)
showed no particular pattern of p53 subcellular immunore-
activity (data not shown).
Relationships between p14ARF and Hdm2 levels of 
expression and subcellular localisation in IDC and DCIS
Hdm2 expression and subcellular distribution were evalua-
ble in 92 (89%) cases of IDC and in 91 cases of DCIS (Fig.
1 and Table 2). Nuclear Hdm2 was detectable (MQS ≥ 3)
in 43 (47%) IDCs with a similar proportion (49 cases) of
cytoplasmic staining (Table 2). A minority of IDCs strongly
expressed nuclear and cytoplasmic Hdm2 (MQS 6–8) in
Table 2
Immunohistochemical MQSs (0–8) for p14ARF, p53 and Hdm2 expression in the nucleus and cytoplasm of invasive ductal cancer and 
ductal carcinoma in situ
Protein Cancer type Location Tumour no. (%) MQS 0–2 (0) MQS 3–5 (1+) MQS 6–8 (2+)
p14ARF Invasive Nucleus 96 20 (21) 31 (32) 45 (47)
Cytoplasm 95 72 (76) 16 (17) 7 (7)
DCIS Nucleus 91 17 (17) 29 (32) 45 (49)
Cytoplasm 91 70 (80) 13 (14) 8 (9)
p53 Invasive Nucleus 93 62 (67) 17 (18) 14 (15)
Cytoplasm 93 70 (75) 18 (19) 5 (5)
DCIS Nucleus 91 66 (73) 12 (13) 13 (14)
Cytoplasm 91 58 (62) 27 (29) 6 (6)
Hdm2 Invasive Nucleus 92 49 (53) 33 (36) 10 (11)
Cytoplasm 91 42 (46) 33 (36) 16 (18)
DCIS Nucleus 91 51 (56) 25 (27) 15 (16)
Cytoplasm 91 43 (47) 27 (30) 21 (23)
Tumour numbers scored (MQS 0–8) by immunohistochemistry for p14ARF, p53 and Hdm2 expression in the nucleus and cytoplasm of invasive 
cancers and ductal carcinoma in situ (DCIS) are shown. Immunohistochemistry expression was assessed individually in the nucleus and the 
cytoplasm, and is defined as negative (0) (MQS 0–2), weak/moderate (1+) (MQS 3–5) and strong (2+) (MQS 6–8). Positivity for p14ARF, p53 
and Hdm2 expression was defined as an MQS of 3 or more (1+/2+).Available online http://breast-cancer-research.com/content/6/5/R571
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10 (11%) and 16 (18%) tumours, respectively. About half
of invasive cancers were negative for nuclear (53%) and
cytoplasmic (46%) Hdm2. A similar pattern for all levels of
Hdm2 expression was seen in DCIS.
Proportional numbers of nuclear p14ARF-expressing breast
cancers (1+/2+) either lacked nuclear Hdm2 expression
(0) (49%, n = 35), as opposed to 51% (n = 37) expressing
nuclear Hdm2 (1+/2+) (Table 3). Nuclear p14ARF showed
no significant associations with nuclear Hdm2 expression
(Fig. 2a). Surprisingly, the minority of cytoplasmic ARF-
expressing breast cancers showed a significant associa-
tion between increasing levels (MQS) of cytoplasmic
p14ARF  and nuclear Hdm2 expression (cc 0.475, P  <
0.001) (Fig. 2c), as well as cytoplasmic Hdm2 expression
(cc 0.461, P < 0.001) (Fig. 2d). Cytoplasmic ARF showed
no other significant associations with p53. There were no
associations between nuclear p53 and Hdm2 levels of
expression or subcellular localisation (Table 3).
Association of p14ARF, p53 and Hdm2 with 
clinicopathological factors
We investigated the relationships between nuclear and
cytoplasmic levels of p14ARF expression and clinicopatho-
logical parameters (listed in Table 1), with ARF MQSs ana-
lysed as a continuum for the purposes of statistical
analysis. There were no significant associations between
either nuclear or cytoplasmic ARF with established prog-
nostic indicators in invasive disease (lymph node involve-
ment, large tumour size > 2 cm, increasing tumour
histological grade, ER negativity, lymphovascular invasion,
NPI and increased proliferation/Ki67), or in DCIS (Van
Nuys Pathologic Classification, ER negativity and
increased proliferation/Ki67). Nuclear ARF expression
(defined as positive [MQS ≥ 3] or negative [MQS < 3])
showed a statistical relationship to HER-2 positivity (2+/
3+) in IDCs (χ2 test, P = 0.038); however, this relates to a
limited number of HER-2-expressing breast cancers (n =
14) in association with ARF. A further subset analysis of
levels of p14ARF expression (negative [0–2], versus weak/
moderate [3–5] versus strong [6–8]; Table 2) in relation to
clinicopathological parameters (data not shown) showed
no significant associations.
Nuclear and cytoplasmic levels of p53 expression
(assessed as a MQS continuum) were analysed in relation
to clinicopathological criteria as for p14ARF. Nuclear p53
levels were significantly associated with increased prolifer-
ation (Ki67) (cc 0.275, P = 0.008) in IDCs, with cytoplas-
mic p53 showing a similar association in DCIS (cc 0.295,
P = 0.005). There was a possible significant trend in IDCs
between nuclear p53 and the NPI (cc 0.210, P = 0.063).
Table 3
Relationships between nuclear expression of p14ARF with nuclear p53 and Hdm2 in invasive breast cancers
Nuclear p14ARF MQS
0 (n = 19) 1+ (n = 28) 2+ (n = 42)
Nuclear p53 MQS 0 (n = 59) 13 21 25
1+ (n =  1 7 ) 251 0
2+ (n =  1 3 ) 427
Nuclear p14ARF MQS
0 (n = 16) 1+ (n = 31) 2+ (n = 41)
Nuclear Hdm2 MQS 0 (n = 48) 13 17 18
1+ (n = 31) 2 10 19
2+ (n =  9 ) 144
Nuclear p53 MQS
0 (n = 58) 1+ (n = 15) 2+ (n = 11)
Nuclear Hdm2 MQS 0 (n = 47) 35 6 6
1+ (n = 34) 23 7 4
2+ (n =  3 ) 021
Tumour numbers scored (MQS 0–8) by immunohistochemistry for nuclear p14ARF are compared with those for nuclear p53; nuclear p14ARF with 
nuclear Hdm2; and nuclear p53 with nuclear Hdm2. Nuclear expression of p14ARF, Hdm2 and p53 is represented as negative (0) (MQS 0–2), 
weak/moderate (1+) (MQS 3–5) and strong (2+) (MQS 6–8). Tumour numbers reflect the combined assessment of protein pairs. Positivity for 
p14ARF, p53 and Hdm2 expression was defined as 1+/2+ (MQS ≥ 3).Breast Cancer Research    Vol 6 No 5    Vestey et al.
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A subset analysis of p53 positivity (MQS ≥ 3) was evalu-
ated in relation to clinicopathological parameters. This
showed that nuclear p53 expression in invasive breast
cancers (MQS ≥ 3 compared with MQS < 3) showed a sig-
nificant correlation with loss of tumour differentiation (cc
0.243, P = 0.019).
We further analysed the relationship between nuclear and
cytoplasmic Hdm2 expression and established parameters
as described (Table 1), using the MQS as a continuum. In
invasive tumours, increasing levels of nuclear and cytoplas-
mic Hdm2 expression were significantly associated with
increased proliferation (Ki67) (cc 0.281, P = 0.007, and cc
0.224, P = 0.032, respectively). In DCIS nuclear Hdm2
was associated with HER-2 overexpression (2+/3+) (cc
0.249, P = 0.019), with no similar association with cyto-
plasmic Hdm2 (cc 0.181, P = 0.09). A further evaluation of
Hdm2 positivity (MQS ≥ 3) to described parameters
showed no other significant associations.
Table 4
Relationships between clinicopathological variables, subcellular Hdm2 and patient outcome
Variable Univariate analysis Multivariate analysis
95% CI P 95% CI P
Overall survival
Age 0.99–1.04 0.4 0.98–2.90 0.009
Lymph node status (+/-) 2.79–153.9 0.004 2.65–161 0.003
Invasive tumour grade (I, II, II) 1.27–4.93 0.002 1.14–4.62 0.002
Tumour size (cm) 1.02–1.05 <0.001 1.02–1.05 <0.001
NPI 1.48–3.36 <0.001 1.39–3.32 <0.001
ER quick-score 0.66–0.92 0.002 0.68–0.98 0.03
HER-2 score 0.94–2.02 0.04 0.76–1.95 0.56
Ki67 proliferative index 0.99–1.00 0.4 0.99–1.00 0.65
Lymphovascular invasion (+/-) 1.46–9.38 0.006 0.89–6.69 0.08
Hdm2 cytoplasm MQS 0.66–0.95 0.01 0.67–0.97 0.02
Hdm2 nucleus MQS 0.68–1.01 0.07 0.69–1.05 0.13
Disease-free survival
Age 0.97–1.02 0.9 0.99–1.06 0.06
Lymph node status (+/-) 2.29–25.3 <0.001 2.06–25.6 0.002
Invasive tumour grade (I, II, II) 1.48–5.38 0.005 1.36–5.11 0.006
Tumour size (cm) 1.02–1.04 <0.001 1.02–1.04 <0.001
NPI 1.46–3.17 <0.001 1.38–3.15 <0.001
ER quick-score 0.66–0.89 0.001 0.68–0.95 0.01
HER-2 score 1.04–1.92 0.02 0.95–1.87 0.2
Ki67 Proliferative index 0.99–1.00 0.2 0.99–1.00 0.3
Lymphovascular invasion (+/-) 1.63–6.95 0.002 1.09–6.65 0.03
Hdm2 cytoplasm MQS 0.73–1.02 0.05 0.70–0.98 0.03
Hdm2 nucleus MQS 0.78–1.09 0.34 0.76–1.09 0.9
Confidence intervals (CI) and P values are given for the results of both the univariate and multivariate analyses. Data for the univariate analysis 
were evaluable in 97 patients (reflecting the exclusion of 6 local tumour recurrences as described in the Methods section) and included a 
multivariate analysis on 86 cases that excluded non-evaluable Nottingham Prognostic Index (NPI) (nodes, grade and size) in 11 patients. All 
clinicopathological variables and subcellular Hdm2 modified Quick-scores (MQSs) were analysed as a continuum, with lymph node status and 
lymphovascular invasion being assessed as present or absent. Univariate and multivariate analyses for cytoplasmic Hdm2 (and nuclear Hdm2) 
(overall survival) were evaluated on 77 and 70 patients, respectively (85 patients univariate [disease-free survival], and 77 patients multivariate, 
[disease-free survival]). The multivariate analysis is adjusted for NPI and treatment (tamoxifen/chemotherapy/none). Relationships that reached 
significance (P < 0.05) are highlighted in bold. ER, oestrogen receptor.Available online http://breast-cancer-research.com/content/6/5/R571
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Relationship of clinicopathological factors to prognosis 
and the predictive potential of p14ARF in relation to p53 
and Hdm2 expression
Overall survival (OS) and disease-free survival (DFS) were
determined in 89 and 97 patients, respectively (primary
tumours), with a median follow-up of 51 months (range 4–
120 months). Disease relapses (local or distant recur-
rences) occurred in 30 women; of these, death was
confirmed in 23 patients, with 8 suspected deaths in the
absence of a recorded mortality date. Locoregional recur-
rence occurred at a median duration of 28.5 months (range
3–120 months) from diagnosis. Breast cancer-related mor-
tality occurred at a median of 26 months (range 8–98
months) from presentation. The mean duration of OS and
DFS were 93 months and 87 months, respectively. Four-
year DFS and OS were 70% and 77%, respectively. The
relationship of established clinicopathological features to
OS and DFS were analysed with Cox's regression analysis
(Table 4). Generally poor prognostic factors such as large
tumour size, high tumour grade, lymph node metastases,
ER negativity, HER-2 overexpression and NPI were signifi-
cantly associated with decreased OS and DFS. High
tumour proliferation (Ki67 on immunohistochemistry),
although associated with a smaller percentage of patients
remaining disease-free (DFS) and alive (OS) at 4 years, did
not reach statistical significance on univariate or multivari-
ate analysis.
Univariate and multivariate analysis with the continuous
MQS variables were used to investigate possible relation-
ships between patient outcome data and levels of subcel-
lular expression for p14ARF, Hdm2 and p53. When scores
were measured as a continuum, neither nuclear nor cyto-
plasmic ARF expression was predictive of OS or DFS after
univariate or multivariate analysis (data not shown). Simi-
larly, a Kaplan–Meier analysis for OS and DFS of the
nuclear p14ARF subgroups (negative [0–2], weak/moderate
[3–5] and strong [6–8]) showed no significant relationship
(data not shown). The small number of patients with strong
cytoplasmic p14ARF precluded a similar analysis (see Table
2). Kaplan–Meier survival curves showed that the presence
of cytoplasmic p14ARF (MQS ≥ 3) might be associated with
a better OS compared with ARF negativity (MQS < 3) (P =
0.09, Fig. 3b), with a similar separation of DFS curves,
although not statistically significant (data not shown). The
presence or absence of nuclear p14ARF (MQS ≥ 3 com-
pared with MQS < 3) was not significantly associated with
patient outcome (Fig. 3a).
Subcellular levels of p53 expression were not shown to be
independent prognosticators for OS and for DFS on univar-
iate or multivariate analyses (data not shown). Kaplan–
Meier analyses of nuclear p53 subgroups (negative [0–2],
weak/moderate [3–5] and strong [6–8]) showed a signifi-
cant association between strong nuclear p53 expression
Figure 3
Relationships between p14ARF and Hdm2 localisation and overall  survival Relationships between p14ARF and Hdm2 localisation and overall sur-
vival. Overall survival curves according to nuclear p14ARF (a), cytoplas-
mic p14ARF (b) and cytoplasmic Hdm2 (c), with patient numbers and 
deaths in parentheses. The classification of 'present' or 'absent' p14ARF 
or Hdm2 expression was determined by an MQS of 3 or more to define 
positivity, compared with an MQS of <3 to define absent expression. 
Patient numbers reflect the exclusion of six local tumour recurrences 
from the analysis of patient outcome and include only recorded deaths 
in 23 patients. P values are given for the log ranks that reached 
significance.
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and a reduced DFS (P = 0.05; log rank), although patient
numbers were small for this group (data not shown). Simi-
larly, nuclear p53 expression (MQS ≥ 3 compared with
MQS < 3) was associated with a reduced OS and DFS,
although this was not statistically significant (data not
shown). Nuclear Hdm2 expression was not an independent
prognosticator for OS and for DFS on univariate or multi-
variate analyses. Cytoplasmic Hdm2 expression (analysed
as a continuous MQS) was associated with improved OS
(P = 0.01, univariate analysis) and DFS (P = 0.05, univari-
ate) (Table 4). Cytoplasmic Hdm2 independently predicted
for improved OS (P = 0.02, multivariate) and DFS (P =
0.03, multivariate) (Table 4). Kaplan–Meier survival curves
showed that the presence of cytoplasmic Hdm2 (MQS ≥ 3
compared with MQS < 3) was associated with improved
OS (P = 0.002) (Fig. 3c).
Discussion
p14ARF suppresses cancer cell growth, and several in vitro
studies have reported its inhibition of Hdm2 to stabilise and
activate p53, with a loss of ARF increasing p53 degrada-
tion. The relevance of these mechanisms in vivo requires
further investigation, in view of ARF's proposed function as
a tumour suppressor and the suggestion that p14ARF over-
expression is a surrogate marker of dysregulation of the
pRb and p53 pathways [30]. p14ARF mRNA expression in
breast cancers underlines a variability with overexpression
in 17–19% and underexpression in 24–26% [38,39].
There are few studies clarifying p14ARF protein levels in
vivo, with low ARF expression in non-neoplastic epithelium
[17,34,35]. The present study suggests an increased fre-
quency of nuclear p14ARF overexpression in 47% of inva-
sive and non-invasive breast cancers. Nuclear p14ARF
overexpression has been shown by immunohistochemistry
in 22% of B cell lymphomas to predict tumour aggression
and outcome [30]. Possible abnormalities in the p53 path-
ways might be implicated [10-14,30,34]. p53-independent
mechanisms might also contribute through oncogenic stim-
ulation of ARF [16,17,30].
The lack of p14ARF expression in 21% of tumours is not dis-
similar to other studies of ARF mRNA levels in breast can-
cers [38,39]. B cell lymphomas lacked nuclear p14ARF in
11% of cases, in association in large part with promoter
hypermethylation, as reported for breast cancers
[21,30,38]. Predominant nucleolar localisation of p14ARF is
determined by amino-terminus and exon 2 carboxy-termi-
nus, with evidence of this after immunofluorescence of a
number of cancer cell lines [25,26] and exclusive nucleolar
p14ARF in a subset of lymphomas and non-tumour tissue
[25,26,30]. The 4C6 monoclonal antibody and other
p14ARF monoclonal antibodies have verified the nuclear/
nucleoplasmic localisation of ARF with intactness of its
functional pathway, as well as its implications as a prognos-
tic surrogate marker compared with nucleolar ARF [27,30].
This study shows nuclear p14ARF in the majority of breast
cancers, with 24% cytoplasmic detection. Few other stud-
ies have attempted to analyse cytoplasmic p14ARF,
although detectable on immunohistochemistry, with in vitro
evidence of an ARF-binding cytoplasmic protein [33-37].
Cytoplasmic p14ARF has been observed in non-small cell
lung cancers, in oral squamous carcinomas and in another
study of lung and pancreatic tumours with the use of sev-
eral monoclonal and polyclonal antibodies [34-37]. This
study analysed cytoplasmic ARF in the context of positive
and sero-matched negative controls as described, with no
evidence of ARF expression in surrounding normal breast
epithelial cells. Such observations might invoke an addi-
tional pathway of ARF regulation through changes in its
subcellular localisation as for other tumour suppressors,
such as p53 and p21WAF1/CIP1  [5,8,51,52]. Similar
genomic aberrations might occur in DCIS and IDC, high-
lighting possible similarities in protein expression [53,54].
This study shows a consistent similarity in levels of protein
expression and subcellular localisation for p14ARF, p53 and
Hdm2 in DCIS and IDCs.
It is suggested that the upregulation of nuclear p14ARF
expression is a consequence of cell cycle malfunction
involving p53 and Hdm2 [30]. Increasing levels of nuclear
ARF on immunohistochemistry are a measure of p53 inac-
tivation by mutation, or by Hdm2 overexpression resulting
in disruption of the p53–p14ARF negative feedback loop
[30]. The implication is that p14ARF expression is associ-
ated with P53-deficient cell lines, suggesting a p53-medi-
ated downregulation of ARF [10-14]. Although p53
immunostaining is not necessarily tightly correlated with
TP53  gene function, 57% (17 cases) of p53-positive
tumours in this study strongly expressed ARF, reflecting
similar  in vivo evidence showing concomitant p14ARF
mRNA expression and p53 immunostaining in breast can-
cers, with a similar relationship between increasing levels
of ARF protein and p53 mutations in B cell lymphomas
(Table 3) [30,34,39]. Others have shown a lack of an
inverse relationship between the two genes, suggesting
that the ARF–p53 pathways are not strictly linear and that
decreased ARF expression and TP53 mutations are not
mutually exclusive [39,55]. ARF stabilises nuclear p53 and
is postulated to congregate with Hdm2 and p53 in ternary
complexes or 'nuclear bodies' that have yet to be demon-
strated in vivo [10,25,27,30].
Double-fluorescent immunolabelling in B cell lymphomas
revealed a partial co-localisation of nuclear p14ARF and
p53, with no Hdm2 association, suggesting that the mech-
anisms underpinning ARF's role in inhibiting the nuclear
export of p53 by Hdm2 inhibition remains to be defined
[30]. Studies in vivo have not previously examined a possi-
ble association between ARF expression and p53 subcel-
lular localisation in breast cancer. In large part, thisAvailable online http://breast-cancer-research.com/content/6/5/R571
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interpretation depends on the accumulation of p53 that is
likely to reflect mutant p53 as inferred from immunohisto-
chemistry [30,34,49]. Proportionately more (55%) p53-
expressing breast cancers showed exclusive nuclear p53
in association with nuclear ARF expression (data not
shown).
Hdm2 expression is a feature of tumorigenesis, with over-
expression attributed in part to gene amplifications in the
minority of breast cancers [56-59]. Other contributing
mechanisms include enhanced transcription and transla-
tion and an extended protein half-life. This study demon-
strates a minority (11%) of Hdm2-overexpressing (MQS 6–
8) invasive breast cancers and 16% of non-invasive breast
cancers. Recent evidence shows that p14ARF overexpres-
sion is associated with increased levels of Hdm2 in cancer
cells, with a similar finding in oral cancers and B cell lym-
phomas that indicate a direct association between p14ARF
and Hdm2 expression determined by immunohistochemis-
try [27,30,35]. Similar findings are reflected in this series of
breast cancers (Table 3).
An additional mechanism of Hdm2-mediated regulation by
p14ARF involves intracellular compartmentation [21]. The
subcellular localisation of Hdm2 involves its nucleolar local-
isation signal, as well as both nuclear import and export
receptors [59]. In vitro immunofluorescent studies verify
the ARF-mediated localisation of Hdm2 in the nucleolus
and nucleoplasm [27]. Not uncommonly in colorectal cell
lines and primary tumours, in vivo inactivation of ARF by
methylation is associated with increasing cytoplasmic
Hdm2 expression, emphasising the importance of p14ARF
in nuclear Hdm2 localisation [21]. ARF-negative cancers,
implying inactivation in this series, show no specific associ-
ation with increased cytoplasmic Hdm2 expression (Fig. 2).
There is a further suggestion in this series of breast cancers
that nuclear ARF expression is associated with both
nuclear and cytoplasmic Hdm2-expressing breast cancers,
underlining the absence of a preferential nuclear localisa-
tion of Hdm2 (data not shown). Similarly, a study of color-
ectal cancers shows the lack of an exclusive relationship
between ARF function and the subcellular localisation of
Hdm2, in comparison with cell lines [21]. HER-2/neuneu
might also regulate the subcellular localisation of Hdm2,
with better prognostic HER-2-negative breast cancers
associated with Hdm2 in both the nucleus and cytoplasm,
in contrast to HER-2-mediated phosphorylation of Hdm2 to
produce its nuclear localisation and the degradation of p53
[60]. Such findings could imply that the relationship
between p14ARF and the subcellular localisation of Hdm2 is
not as exclusive as that found in cell lines.
Clinically, the implications of p14ARF levels of expression in
breast cancer are unknown; two previous studies examined
p14ARF  mRNA expression in relation to prognostic
parameters [38,39]. Variable p14ARF  mRNA expression
including both overexpression as well as decreased mRNA
levels are reported to be significantly associated with poor
prognostic criteria including p53 mutational status, peritu-
moural vessel invasion, lymph node metastases and nega-
tive progesterone receptors [38,39]. By comparison,
nuclear p14ARF overexpression in B cell lymphomas with
the use of immunohistochemistry predicts tumour aggres-
sion and reduced overall survival [30]. We find no clear
associations between ARF levels and prognostic parame-
ters or outcome, although the presence of cytoplasmic
p14ARF as opposed to its absence suggests a better out-
come (Fig. 3b). At present, a poor understanding of the
implications of cytoplasmic ARF expression in tumours
requires further study [35-37]. In vitro, HER-2/neuneu
interacts with the p14ARF/Hdm2 pathway; some in vivo
studies show that p14ARF mRNA overexpression in breast
cancers is correlated with HER-2 negativity [38,39,61]. In
vitro, HER-2 promotes Hdm2-mediated p53 degradation
through the inactivation of ARF, and HER-2 further
enhances mammary tumorigenesis in ARF  heterozygous
mice [60,61]. Our finding of an association between ARF
and HER-2 expression is preliminary and suggests the
importance of HER-2 in the ARF pathway.
Inactivation of p53 might occur through pathways other
than mutation, involving p14ARF/Hdm2 and its degradation
through subcellular localisation. Immunohistochemical p53
expression might detect up to 89% of TP53 point muta-
tions in breast carcinoma specimens, although it does not
always correlate with specific mutations in exons 5 to 9
[34,49]. Despite an established body of literature regarding
the implications of p53 nuclear immunoreactivity, few or no
in vivo studies have evaluated cytoplasmic p53. The cyto-
plasmic localisation of p53 is a prerequisite for its proteo-
somal degradation and has been implicated in patient
prognosis [5,62]. A study of inflammatory breast cancers
showed the presence of wild-type cytoplasmic p53 in 37%
of cases [5]. We found a significant association of cyto-
plasmic p53 with increased tumour proliferation in DCIS,
suggesting the value of its further investigation in future
studies. Similarly, Hdm2 undergoes nucleocytoplasmic
shuttling; highly proliferative, invasive breast cancers were
associated with increasing levels of nuclear or cytoplasmic
Hdm2 expression in this study. Immunohistochemical p53
and Hdm2 expression were also shown to be correlated
with ki67 in B cell lymphomas [30]. A possible functional
relevance of subcellular Hdm2 expression is suggested,
although Ki67 was not an independent prognosticator in
this study.
Our findings of an association between HER-2 and nuclear
Hdm2 expression might support in vivo findings in which
HER-2, through phosphoinositide 3-kinase/Akt-mediated
phosphorylation, is preferentially associated with nuclearBreast Cancer Research    Vol 6 No 5    Vestey et al.
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Hdm2 [60]. In the present study the association between
the presence of cytoplasmic Hdm2 and improved outcome
would initially seem counterintuitive, yet it is substantiated
by recent evidence that HER-2-negative and Akt-negative
cell lines are associated predominantly with cytoplasmic
Hdm2 [60]. In vivo, the study of a small subset of breast
cancers (21 tumours) confirmed these in vitro findings,
suggesting an important relationship between HER-2 acti-
vation and the p14ARF/Hdm2 and p53 pathways [60].
Conclusion
Defining relevant pathways regulating p53 function are fun-
damental to an understanding of its tumour suppressor role
and mechanisms of p53 inactivation, which might be inde-
pendent of a p53 mutation. p14ARF and Hdm2 are key
upstream and downstream regulators of p53, although in
part they might be independent of p53. We have demon-
strated a spectrum of tumour-specific p14ARF upregulation
with predominant nuclear ARF expression in the absence of
exclusive nucleolar staining in invasive and non-invasive
breast cancers; we suggest that the presence of cytoplas-
mic p14ARF might be favourable in terms of breast cancer
outcome. Predominant nuclear ARF levels showed no clear
clinical implications about the degree of ARF expression
versus its negativity. Clearly our in vivo findings do not com-
pletely mirror in vitro relationships between p14ARF/Hdm2
and p53 to suggest a greater complexity of these pathways
in human solid tumours. Increasingly, evidence suggests
the importance of evaluating the subcellular localisation of
checkpoint proteins to include p53, Hdm2 and p14ARF
[51,52]. Potentially, changes in the cellular distribution of
these proteins might be driven by key tumorigenic proc-
esses to which HER-2 and other growth factor pathways
might contribute.
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